ABILITYPHARMA

AbilityPharma is a clinical stage phase 2b biopharmaceutical company focused on autophagy to treat cancer

PIPELINE

ABTL0812, first-in-class, is currently in phase 2b clinical trials in pancreatic cancer in Spain, USA, France, and Israel. The product has also completed with positive results a phase 2a trial in endometrial cancer and lung cancer in Spain and France. 

SCIENCE

AbilityPharma investigates cancer drugs inducing cytotoxic autophagy selectively in cancer cells

AbilityPharma is a biopharmaceutical company developing new first-in-class candidates to treat cancer. We are focused on autophagy as a new therapeutic strategy to induce cancer cell death. Based on this novel mechanism of action, we are generating a portfolio of new drugs targeting oncological unmet needs.

Media Center

11.05.2021

Press Release

Ability Pharmaceuticals Announces the Inclusion of the First Patients in a Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as First Line Therapy in Advanced Pancreatic Cancer simultaneously in USA and Europe + info
28.12.2020

Press Release

The Chinese pharmaceutical company SciClone joins the capital of AbilityPharma with an investment commitment of three million dollars + info
29.12.2020

In the media

The Chinese SciClone becomes shareholder of Ability Pharma with € 2.5 million + info
29.12.2020

In the media

The Chinese SciClone enters at the biotech Ability Pharma + info
September

Events

BioSpain. Pamplona + info
May

Events

Anglonordic. Digital + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG